Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
•
Breast Cancer, Metastatic
How do you approach treatment in a young de novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Related Questions
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
What are your top takeaways from ESMO 2023?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
What disease characteristics will guide your choice of alpelisib plus fulvestrant (per SOLAR-1) versus capivasertib plus fulvestrant (per CAPItello-291) in Pik3ca mutated advanced ER+/HER2- breast cancer after progression on 1L ET regimen, given both are now approved in this population?
Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?
In a patient with metastatic HR+/HER2- breast cancer who progressed on adjuvant hormonal therapy, do you start fulvestrant + CDK4/6i or do you wait for NGS testing to determine eligibility for targeted agents such as elacestrant or PIK3CA inhibitors?
What are your top takeaways from SABCS 2023?
How would you treat a patient with T1c HR-, HER2+ breast cancer, stage IV, with involvement of multiple bilateral axillary nodes and no evidence of distant metastasis?
